The company processes and distributes medical X-ray films and industrial non-destructive testing equipment, primarily serving healthcare facilities and industrial sectors like aerospace and oil and gas.
The company operates in a commoditized trading and job-work environment with low returns on capital (7.7% ROCE) and no evidence of brand or scale advantages. The transition from medical films to industrial testing is a pivot to avoid a sunset industry rather than an expansion of a competitive moat.
Capital has been focused on a major merger to pivot the business model away from declining film sales. Historically, the company has struggled to generate meaningful returns, and executive directors only recently resumed taking salaries after a multi-year waiver, suggesting past financial stress.
The company's pivot into industrial testing failed to generate scale, while the massive contingent liability for customs duties—nearly equal to annual revenue—was ruled against them, wiping out the balance sheet. Management's decision to resume executive salaries despite inadequate profits signaled a lack of stewardship, and the business eventually succumbed to its low-margin, commoditized nature, leaving shareholders with a hollowed-out shell that could no longer cover its cost of capital.
RichFakir rates Choksi Asia Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Choksi Asia Ltd is trading about 78% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Choksi Asia Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Choksi Asia Ltd's fair value is about ₹119 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →